Navigation Links
Exhaustive Study to Expand the Efficacy of Drug L-dopa for Parkinson's

Parkinson's sufferers are usually treated with the drug called levodopa or L-dopa that helps in reviving cellular communication//. After prolonged use of the drug, many patients may experience motor complications and a reduced response to the drug.

Parkinson's disease is a slow process of destruction of brain cells which produce dopamine. As dopamine levels fall, the symptoms of Parkinson’s shows up as tremors in the arms, legs and face. The patients visibly portray slow movement, lack of proper balance and coordination.

A new clinical trial is underway to evaluate the effectiveness of a novel drug to treat Parkinson’s, which could extend the benefits of he existing drug, L-dopa. The study will also investigate the potential of the drug, E2007, and its contribution in extending the effectiveness of L-dopa.

The prevailing treatment for Parkinson's disease aims to revive cellular communication by simply restoring the lost dopamine with L-dopa. Though this therapy is effective for sometime, yet it is unable to halt the gradual decline so evident in long time Parkinson’s sufferers.

"The hope is that by altering dopamine transmission through the modulating the activity of AMPA receptors, there will be measurable effects on the dopamine system," said Dr. Liang.

The study has been tailored to suit patients suffering advanced Parkinson's and have been undergoing L-dopa treatment for a considerable period of time. The study will involve nearly 700 patients from more than 100 centers across the U.S., Canada, Australia, New Zealand and South America.

Dr. Kremens said, "It's an interesting approach and an exciting trial because it is exploring a drug in a new therapeutic category. L-dopa is still the gold standard and we haven't come up with a better dopamine as yet."
'"/>




Page: 1

Related medicine news :

1. Dolly Paves the Way for Exhaustive Stem Cell Research
2. Cancer Drug Helps An Anti-Cancer Virus To Act More Exhaustively
3. Tomato Sauce reduces Cancer Risk- Study
4. Study on obesity and heart failure
5. National Lung Study in the process
6. Study casts doubt on keyboard ills
7. Study reveals how stress can make you sick
8. Study reveals how stress can make you sick
9. Study supports vegetable diet
10. Study to look at early surgery to treat epilepsy
11. Its Never Too Late to Stop Smoking,Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... ... , ... Public relations pros work hard to earn placements and build ... many results are clear, much of PR is hard to quantify. Goal-setting and measurement ... measurement, firms should always take an all-inclusive approach that takes both traditional and non-traditional ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended ... , This event was exclusive to providers and offered an opportunity to collaborate ... place at the Manchester Grand Hyatt where attendees gathered for a lively discussion on ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected ... who want straight teeth without the extensive time commitment and aesthetic disadvantages of ... acquiring a referral. A custom-designed series of virtually invisible aligners are created for ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... LightIntegra Technology Inc. today announced that its ... President and Chief Executive Officer effective March 13, 2017. ... Directors of LightIntegra. Paul Geyer will continue ... "This is the perfect time for Bill ... We,ve selected a very strong leader at a time ...
(Date:3/27/2017)...  A new survey from the American ... Bidding Program (CBP) significantly reduced beneficiary choice and access ... choice forces beneficiaries to switch to unfamiliar or unsuitable ... AADE,s survey is the latest in a ... out the inherent problems with the CBP. Last year, ...
Breaking Medicine Technology: